News Image

When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

By Mill Chart

Last update: May 8, 2024

Discover HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock highlighted by our stock screener. NASDAQ:HALO showcases solid financial health and profitability while maintaining an appealing valuation. We'll explore the details.

A Closer Look at Valuation for NASDAQ:HALO

ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:HALO boasts a 8 out of 10:

  • Based on the Price/Earnings ratio, HALO is valued cheaply inside the industry as 97.09% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of HALO to the average of the S&P500 Index (28.11), we can say HALO is valued slightly cheaper.
  • Based on the Price/Forward Earnings ratio of 10.96, the valuation of HALO can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, HALO is valued cheaply inside the industry as 98.46% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 20.39, HALO is valued a bit cheaper.
  • 96.58% of the companies in the same industry are more expensive than HALO, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, HALO is valued cheaply inside the industry as 98.12% of the companies are valued more expensively.
  • HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HALO has a very decent profitability rating, which may justify a higher PE ratio.
  • HALO's earnings are expected to grow with 30.48% in the coming years. This may justify a more expensive valuation.

Profitability Insights: NASDAQ:HALO

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:HALO was assigned a score of 7 for profitability:

  • HALO has a better Return On Assets (16.25%) than 98.97% of its industry peers.
  • The Return On Equity of HALO (335.99%) is better than 100.00% of its industry peers.
  • HALO has a Return On Invested Capital of 17.00%. This is amongst the best in the industry. HALO outperforms 98.29% of its industry peers.
  • HALO had an Average Return On Invested Capital over the past 3 years of 17.78%. This is above the industry average of 14.11%.
  • HALO has a better Profit Margin (33.96%) than 99.15% of its industry peers.
  • HALO has a better Operating Margin (41.02%) than 99.49% of its industry peers.
  • Looking at the Gross Margin, with a value of 76.82%, HALO belongs to the top of the industry, outperforming 86.15% of the companies in the same industry.

Understanding NASDAQ:HALO's Health Score

A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:HALO has received a 7 out of 10:

  • HALO has an Altman-Z score of 3.54. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of HALO (3.54) is better than 75.56% of its industry peers.
  • HALO has a better Debt to FCF ratio (4.02) than 95.21% of its industry peers.
  • A Current Ratio of 6.64 indicates that HALO has no problem at all paying its short term obligations.
  • HALO's Current ratio of 6.64 is fine compared to the rest of the industry. HALO outperforms 65.81% of its industry peers.
  • HALO has a Quick Ratio of 5.50. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.

A Closer Look at Growth for NASDAQ:HALO

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:HALO was assigned a score of 9 for growth:

  • The Earnings Per Share has grown by an impressive 25.23% over the past year.
  • The Earnings Per Share has been growing by 45.64% on average over the past years. This is a very strong growth
  • The Revenue has grown by 25.59% in the past year. This is a very strong growth!
  • Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 40.42% on average per year.
  • HALO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.93% yearly.
  • Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 13.80% on average per year.

More Decent Value stocks can be found in our Decent Value screener.

Our latest full fundamental report of HALO contains the most current fundamental analsysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (5/17/2024, 7:03:22 PM)

After market: 44.9 +0.19 (+0.42%)

44.71

-0.68 (-1.5%)

HALO News

News Image2 days ago - Market News VideoHALO July 19th Options Begin Trading
News Image3 days ago - Investor's Business DailyHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating

On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

News Image5 days ago - Investor's Business DailyCatalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating

On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.

News Image5 days ago - ChartmillWhile growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.

Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.

News Image10 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...

News Image10 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...

News Image11 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in May 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

News Image11 days ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present...

News Image11 days ago - ChartmillWhen you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

News Image12 days ago - InvestorPlaceHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image12 days ago - BusinessInsiderHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Halozyme Therapeutics (NASDAQ:HALO) just reported results for the first quarter...

News Image12 days ago - Halozyme Therapeutics, Inc.HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0....

HALO Links
Follow us for more